Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.

ABSTRACT:

Background

Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme CYP2C9 and the Vitamin K-activating enzyme VKORC1. In the WARIS-II study, comparing three different antithrombotic regimens after myocardial infarction, warfarin treatment reduced thrombotic events, but was associated with more frequent bleeding than use of acetylsalisylic acid (ASA) alone.

Aims

The primary aim of the present study was to investigate the relation between genotypes of CYP2C9 and VKORC1 and warfarin maintenance dose in myocardial infarction. The secondary aim was to relate the genotypes to international normalized ratio (INR).

SUBMITTER: Haug KBF 

PROVIDER: S-EPMC2440373 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature